There is precedent for potential therapeutic value of antibody neutralization of CGB proteins in the form of anti-cancer vaccines (Moulton 2002), and an anti-CGB therapeutic antibody could potentially provide therapeutic value on its own, or to provide specificity to a coupled anti-cancer payload. The gene discussed is CGB5; the disease is cancer.